AVAILABLENCT06731036
Expanded Access to CD34+ Selection Utilizing Miltenyi CliniMACS Prodigy® for Patients Receiving Peripheral Blood Stem Cell Transplantations and Stem Cell Boosts
Studying T-B+ severe combined immunodeficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Florida
- Principal Investigator
- Jordan Milner, MD, MDUniversity of Florida
- Intervention
- CD34+ cell enriched stem cell graft(biological)
- Eligibility
- All sexes
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06731036 on ClinicalTrials.govOther trials for T-B+ severe combined immunodeficiency
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT06851767Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene TherapyNational Institute of Allergy and Infectious Diseases (NIAID)
- ACTIVE NOT RECRUITINGPHASE2NCT03619551Conditioning SCID Infants Diagnosed EarlyCenter for International Blood and Marrow Transplant Research
- RECRUITINGPHASE1, PHASE2NCT01306019Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)National Institute of Allergy and Infectious Diseases (NIAID)